Pat Barry serves as Executive Vice President and Chief Commercial Officer at Indivior plc, a global pharmaceutical company dedicated to addressing opioid use disorder and serious mental health conditions. In this pivotal role, Barry oversees the company's global commercial operations, including sales, marketing, market access, and pricing strategies. He plays a key part in driving the commercialization of Indivior's innovative portfolio, such as SUBLOXONE and OPVEE, ensuring sustainable growth and expanded access to treatments that transform patient lives. With over 25 years of experience in the biopharmaceutical industry, Barry brings a proven track record of building high-performing commercial organizations. Prior to joining Indivior in April 2021, he served as Senior Vice President and Head of U.S. Commercial Operations at Alkermes plc, where he led the launch and successful market penetration of VIVITROL for alcohol and opioid dependence, significantly increasing market share and revenue. Earlier in his career, Barry held progressive leadership positions at Reckitt Benckiser, the predecessor to Indivior, honing his expertise in CNS therapeutics and addiction treatments. Barry's achievements include spearheading multi-billion-dollar product launches, fostering cross-functional teams to navigate complex regulatory environments, and delivering double-digit growth in competitive markets. His strategic vision has been instrumental in Indivior's evolution, positioning the company as a leader in addiction medicine while prioritizing patient-centric innovation and ethical commercial practices.